Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-methyl-N-propenyl-1,2,3,4-tetrahydroisoquinoline
- Development stage
- Preclinical
- Lead developer
- Musashino University
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
1-methyl-N-propenyl-1,2,3,4-tetrahydroisoquinoline (1-Me-N-propenyl-TIQ) is a synthetic derivative of the endogenous neuroprotective agent 1-methyl-1,2,3,4-tetrahydroisoquinoline (1-MeTIQ). It has been investigated for its potential therapeutic effects in Parkinson's disease models, specifically for its ability to alleviate motor symptoms. In preclinical studies using MPTP-treated mice, 1-Me-N-propenyl-TIQ demonstrated a significant reduction in bradykinesia. However, unlike its N-propargyl counterpart, it failed to provide significant neuroprotection against the loss of striatal dopamine, nigral tyrosine hydroxylase-positive neurons, or the downregulation of the dopamine transporter (DAT). This suggests that while the propenyl modification confers some symptomatic benefit, it does not share the potent neuroprotective profile of the alkynyl-substituted derivatives in this chemical series.
- Other names
- 1-methyl-N-propenyl-tetrahydroisoquinolineN-propenyl-1-methyl-1,2,3,4-tetrahydroisoquinoline
02
Targets
DAT (Dopamine plasma membrane transport protein)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on 1-methyl-N-propenyl-1,2,3,4-tetrahydroisoquinoline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1-methyl-N-propenyl-1,2,3,4-tetrahydroisoquinoline.